| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSMb6 |
| Uniprot No | P28072 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-239aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMTTIMAVQFDGGVVLGADSRTTTGSYIANR VTDKLTPIHDRIFCCRSGSAADTQAVADAVTYQLGFHSIELNEPPLVHTA ASLFKEMCYRYREDLMAGIIIAGWDPQEGGQVYSVPMGGMMVRQSFAIGG SGSSYIYGYVDATYREGMTKEECLQFTANALALAMERDGSSGGVIRLAAI AESGVERQVLLGDQIPKFAVATLPPA |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSMb6重组蛋白的模拟参考文献示例(注：内容为虚构，仅作参考格式示范)：
---
1. **文献名称**：Expression and purification of recombinant human proteasome subunit beta 6 in Escherichia coli
**作者**：Smith, J. et al.
**摘要**：该研究报道了通过大肠杆菌表达系统成功克隆并纯化人源PSMb6重组蛋白，优化了诱导条件以提高可溶性表达，并通过质谱验证其正确折叠及蛋白酶体复合物中的功能活性。
2. **文献名称**：Structural insights into PSMb6 function using recombinant protein crystallography
**作者**：Zhang, L. et al.
**摘要**：利用昆虫细胞表达系统获得高纯度PSMb6重组蛋白，解析其晶体结构，揭示了其底物结合位点的关键氨基酸残基，为靶向蛋白酶体抑制剂的设计提供依据。
3. **文献名称**：PSMb6 recombinant protein as a tool for screening proteasome inhibitors in cancer therapy
**作者**：Lee, S. et al.
**摘要**：研究开发了基于重组PSMb6的高通量药物筛选平台，验证其对特定抑制剂(如硼替佐米)的敏感性，证明其在肿瘤治疗中作为药物靶点的潜力。
4. **文献名称**：Comparative analysis of PSMb6 expression systems: Yeast vs. mammalian cell lines
**作者**：Johnson, R. et al.
**摘要**：对比酵母和哺乳动物细胞表达PSMb6重组蛋白的效率，发现哺乳动物系统更适于维持其天然构象，但酵母系统在成本效益上具有优势。
---
实际研究中请通过PubMed或Web of Science等数据库检索真实文献。
PSMb6. also known as Proteasome Subunit Beta 6 or β6. is a critical component of the 20S core particle of the proteasome, a large multi-catalytic protease complex responsible for regulated protein degradation in eukaryotic cells. As a catalytic subunit, it harbors a conserved N-terminal threonine residue that acts as the active site for proteolytic activity, specifically chymotrypsin-like cleavage. The proteasome plays a central role in maintaining cellular homeostasis by degrading misfolded, damaged, or ubiquitin-tagged proteins via the ubiquitin-proteasome system (UPS), thereby regulating processes like cell cycle progression, apoptosis, and immune response.
Recombinant PSMb6 refers to the β6 subunit produced through genetic engineering techniques, typically expressed in heterologous systems such as *E. coli* or mammalian cell lines (e.g., HEK293). Its recombinant form enables detailed biochemical and structural studies, including enzymatic activity assays, inhibitor screening, and crystallography. This subunit is of particular interest in drug discovery, as proteasome inhibitors (e.g., bortezomib) targeting catalytic subunits have been developed for treating hematologic malignancies like multiple myeloma. Mutations in PSMb6 have also been linked to autoimmune disorders and neurodegenerative diseases, making it a focus for mechanistic research.
The production of recombinant PSMb6 often involves codon optimization, affinity tag fusion (e.g., His-tag), and purification via chromatography. Its functional characterization helps elucidate proteasome assembly, substrate specificity, and interactions with regulatory particles (e.g., 19S). Additionally, engineered PSMb6 variants are used to study resistance mechanisms to proteasome inhibitors or to design next-generation therapeutics. Overall, recombinant PSMb6 serves as a vital tool for advancing our understanding of proteasome biology and its therapeutic implications.
×
